GeneFo’s Guide Can Help Parkinson’s Patients Apply for Medical Cannabis
GeneFo has created a free state-by-state guide for Parkinson’s patients with detailed and relevant information on medical cannabis, including the application process.
Medical Cannabis in Parkinson Disease: Real-Life Patients’ Experience
The survey used telephone interviews using a structured questionnaire based on subjective global impressions of change for various parkinsonian symptoms and yes/no questions on adverse effects. Medical cannabis was found to improve symptoms of PD in the initial stages of treatment and did not cause major adverse effects in this pilot, 2-center, retrospective survey. The extent of use and the reported effects lend support to further development of safer and more effective drugs derived from Cannabis sativa.
Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson’s disease
Cannabis can alleviate pain of various etiologies. This study assessed the effect of cannabis on motor symptoms and pain parameters in patients with Parkinson’s disease (PD). Quantitative sensory test results are significantly altered following cannabis consumption in patients with PD. Cannabis probably acts on pain in PD via peripheral and central pathways.
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study
The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess the clinical effect of cannabis on motor and non-motor symptoms of PD. The study suggests that cannabis might have a place in the therapeutic armamentarium of PD. Larger, controlled studies are needed to verify the results.
Cannabis use in people with Parkinson’s disease and Multiple Sclerosis: A web-based investigation
Cannabis has been used for medicinal purpose for thousands of years; however the positive and negative effects of cannabis use in Parkinson’s disease (PD) and Multiple Sclerosis (MS) are mostly unknown.Our aim was to assess cannabis use in PD and MS and compare results of self-reported assessments of neurological disability between current cannabis users and non-users. Further studies using clinically and longitudinally assessed measurements of these domains are needed to establish if these associations are causal and determine the long-term benefits and consequences of cannabis use in people with PD and MS.